Targeting hematological malignancies with isoxazole derivatives

• Type: Another Publication in an International Scientific Journal
• Date: 2024

Authors

Majirská, M (Author) Other; Pilátová, MB (Author) Other; Kudlicková, Z (Author) Other; Vojtek, M (Author) Other; Diniz, C (Author) FFUP

Journal

Title: Drug Discovery Today

Vol. 29

ISSN: 1359-6446

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-010-YQT

DOI: 10.1016/j.drudis.2024.104059

Abstract (EN): Compounds with a heterocyclic isoxazole ring are well known for their diverse biologic activities encompassing antimicrobial, antipsychotic, immunosuppressive, antidiabetic and anticancer effects. Recent studies on hematological malignancies have also shown that some of the isoxazole-derived compounds feature encouraging cancer selectivity, low toxicity to normal cells and ability to overcome cancer drug resistance of conventional treatments. These characteristics are particularly promising because patients with hematological malignancies face poor clinical outcomes caused by cancer drug resistance or relapse of the disease. This review summarizes the knowledge on isoxazole-derived compounds toward hematological malignancies and provides clues on their mechanism(s) of action (apoptosis, cell cycle arrest, ROS production) and putative pharmacological targets (c-Myc, BET, ATR, FLT3, HSP90, CARM1, tubulin, PD-1/PD-L1, HDACs) wherever known.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 23